The CD4+ T cell repertoire specific for citrullinated peptides shows evidence of immune tolerance

J Exp Med. 2023 Dec 4;220(12):e20230209. doi: 10.1084/jem.20230209. Epub 2023 Oct 13.

Abstract

Rheumatoid arthritis occurs most often in people who express HLA-DR molecules containing a five aa "shared epitope" in the β chain. These MHCII molecules preferentially bind citrullinated peptides formed by posttranslational modification of arginine. Citrullinated peptide:HLA-DR complexes may act as arthritis-initiating neo-antigens for CD4+ T cells. Here, we used fluorophore-conjugated HLA-DR tetramers containing citrullinated peptides from human cartilage intermediate layer protein, fibrinogen, vimentin, or enolase 1 to track cognate CD4+ T cells. Immunization of HLA-DR transgenic mice with citrullinated peptides from vimentin or enolase 1 failed to cause any expansion of tetramer-binding cells, whereas immunization with citrullinated peptides from cartilage intermediate layer protein or fibrinogen elicited some expansion. The expanded tetramer-binding populations, however, had lower T helper 1 and higher regulatory T cell frequencies than populations elicited by viral peptides. These results indicate that HLA-DR-bound citrullinated peptides are not neo-antigens and induce varying degrees of immune tolerance that could pose a barrier to rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Arthritis, Rheumatoid*
  • CD4-Positive T-Lymphocytes*
  • Citrullination
  • Fibrinogen
  • HLA-DR Antigens
  • Humans
  • Immune Tolerance*
  • Mice
  • Mice, Transgenic
  • Peptides
  • Peptides, Cyclic
  • Phosphopyruvate Hydratase / metabolism
  • Vimentin / chemistry

Substances

  • Fibrinogen
  • HLA-DR Antigens
  • Peptides
  • Peptides, Cyclic
  • Phosphopyruvate Hydratase
  • Vimentin